Dr. Jeffrey Jones on Efficacy of Idelalisib/Ofatumumab Combination in CLL

Video

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

Jeffrey Jones, MD, MPH, Assistant Professor of Internal Medicine and section head of the Chronic Lymphocytic Leukemia (CLL) research program at Ohio State University, discusses the results of a phase III randomized, controlled study evaluating idelalisib (Zydelig) in combination with ofatumumab (Arzerra) compared to ofatumumab alone for previously treated CLL.

The number of agents that have traditionally been available for patients with relapsed or refractory CLL has been limited, says Jones. Patients in this study received 6 months of ofatumumab in both arms, and patients in the combination arm received twice-daily idelalisib to be continued until disease progression or intolerable side effects.

Progression-free survival was significantly improved in the combination arm, with a median progression-free survival of just over 16 months, compared to 8 months in the ofatumumab-only arm, says Jones. The overall response rate was 75% in the combination arm versus 18% in the single agent arm.

<<<

View more from the 2015 ASCO Annual Meeting

Related Videos
Alexey Danilov, MD, PhD
Hayder Saeed, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
A panel of 6 experts on chronic lymphocytic leukemia seated at a long desk